Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15716501 | 0.92 | CHRNB2 (0.58) | CHRNB2CHRNA4KDM4ECYP1A2CYP2D6 | |
| SCHEMBL14941165 | 0.86 | CHRNB2 (0.59) | CHRNB2CHRNA4KDM4ECYP1A2CYP2D6 | |
| SCHEMBL188620 | 0.84 | CHRNB2 (0.58) | CHRNB2CHRNA4 | |
| SCHEMBL24568237 | 0.82 | CHRNB2 (0.64) | CHRNB2CHRNA4 | |
| SCHEMBL29318733 | 0.82 | CHRNB2 (0.52) | CHRNB2CHRNA4 | |
| SCHEMBL29318218 | 0.82 | CHRNB2 (0.38) | CHRNB2CHRNA4KDM4ECYP1A2CYP2D6 | |
| SCHEMBL3103772 | 0.82 | CHRNB2 (0.52) | CHRNB2CHRNA4KDM4ECYP1A2CYP2D6 | |
| SCHEMBL25447379 | 0.81 | CHRNB2 (0.49) | CHRNB2CHRNA4KDM4ECYP1A2CYP2D6 | |
| SCHEMBL29318739 | 0.80 | CHRNB2 (0.57) | CHRNB2CHRNA4 | |
| SCHEMBL19959133 | 0.78 | CHRNB2 (0.62) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239756-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239756-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | ENPP2, SSB, PLPBP | CHRNB2 2532/4885CHRNA4 2107/4885ATM 4157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.